U.S. Could Authorize Novavax Covid Vaccine—An MRNA Alternative—In February, CEO Says

The Covid-19 vaccine could be approved for use in the US in February and in up to 10 other countries within 90 days.

The vaccine may be approved by the FDA in February.

Agence France-Presse via Getty Images

The company will not be able to request emergency use authorization until January 31, after it submitted its final data packages to the FDA.

The vaccine has been submitted for use in Australia, Canada, New Zealand, Singapore, South Africa and the U.K., and the company expects it to be approved in multiple countries over the next 90 days.

Erck said that the vaccine stimulates the immune system using nanoparticles, rather than the traditional method of using mRNA.

Novavax's vaccine stimulates the immune system by introducing a particle from the coronaviruses that cannot cause illness, but it does not cause illness. Novavax's vaccine can be stored at room temperature, which makes it much easier to distribute than the mRNA vaccines. The vaccine was found to be effective against the coronaviruses, according to the WHO. In November, Indonesia became the first country to issue an emergency use authorization for the vaccine, which has since been made available for use in 170 countries. In the first quarter of the year, 27 million vaccine doses will be shipped, and over 40 million in the second quarter. Erck said that Novavax is contracted to deliver 2 billion doses of vaccine.

We don't know what we don't know.

The WHO said it was not certain how Novavax's vaccine stacks up against the omicron variant. Data shows that a Novavax booster shot increases levels against omicron more effectively than Pfizer or Moderna.

What to watch for.

Gregory M. Glenn, president of research and development for Novavax, said that clinical studies of an omicron-targeted vaccine will begin in the first quarter of 2022. There are trials for a vaccine that protects against Covid and flu.

Novavax had manufacturing problems that slowed their entry into the vaccine market. After Erck told CNBC he expected the vaccine to win emergency use authorization from 10 regulatory agencies within 90 days, Novavax shares were up 4.16% on Monday afternoon.

The Covid vaccine could be cleared in multiple countries over the next 90 days according to the CEO.

Data suggests thatNovavax Covid Vaccine provides a response against Omicron.